Skip to main content
Erschienen in: Rheumatology International 1/2012

01.01.2012 | Original Article

Factors and comorbidities associated with central nervous system involvement in systemic lupus erythematosus: a retrospective cross-sectional case–control study from a single center

verfasst von: Melissa Padovan, Gabriella Castellino, Alessandra Bortoluzzi, Luisa Caniatti, Francesco Trotta, Marcello Govoni

Erschienen in: Rheumatology International | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

To evaluate, by a retrospective cross-sectional case–control study from a single center, the distribution of a number of factors and comorbidities potentially related to central nervous system involvement in SLE Italian patients, a number of “generic” (i.e. not strictly SLE related) and “specific” (i.e. SLE related) risk factors were checked and their distribution analyzed in SLE patients with (NPSLE) and without (SLE) neuropsychiatric (NP) involvement. One hundred and fifty-three SLE patients with NP involvement observed from 1999 to 2008 and 247 SLE patients without NP manifestations, matched for sex, age and disease duration were included in the study. A neuropsychiatric (NP) event represented the heralding symptom of the disease in 40.5% of NPSLE. Headache, cerebrovascular events, mood disorders and seizures were the most frequent NP manifestations. NPSLE patients had a major cumulative number of the investigated factors than controls without NP involvement. Antiphospholipid antibodies (aPL), lupus anticoagulant (LA), Antiphospholipid antibodies syndrome (APS), Raynaud’s phenomenon, smoke, assumption of contraceptives and higher cumulative dose of glucocorticosteroids (GC) were significantly more commonly observed among NPSLE. APS and systemic arterial hypertension were more frequently detected among patients with focal NP manifestations, especially cerebrovascular events. aPL, LA, APS, Raynaud’s phenomenon, smoke, contraceptives intake and higher cumulative dose of GC did prove more frequently detected in NPSLE patients than in controls. In particular, overall, arterial hypertension should be regarded as a potential independent “risk factor” for focal involvement, especially for cerebrovascular events.
Literatur
1.
Zurück zum Zitat ACR ad hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology (1999) Arthritis Rheum 42:599–608 ACR ad hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology (1999) Arthritis Rheum 42:599–608
2.
Zurück zum Zitat Unterman A, Nolte JES, Boaz M et al (2009) The prevalence of neuropsychiatric syndromes in sle: a metanalysis. 2009 annual scientific meeting of the American college of rheumatology, Philadelphia 16–21 October. Arthritis Rheum 60(suppl):S589 Unterman A, Nolte JES, Boaz M et al (2009) The prevalence of neuropsychiatric syndromes in sle: a metanalysis. 2009 annual scientific meeting of the American college of rheumatology, Philadelphia 16–21 October. Arthritis Rheum 60(suppl):S589
3.
Zurück zum Zitat Hanly JG, Walsh NMG, Sangalang V (1992) Brain pathology in systemic lupus erythematosus. J Rheumatol 19:732–741PubMed Hanly JG, Walsh NMG, Sangalang V (1992) Brain pathology in systemic lupus erythematosus. J Rheumatol 19:732–741PubMed
4.
Zurück zum Zitat Tan EM, Cohen AS, Fries JF, Masi AT, McShone DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef Tan EM, Cohen AS, Fries JF, Masi AT, McShone DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef
5.
Zurück zum Zitat Castellino G, Padovan M, Bortoluzzi A, Borrelli M, Feggi L, Caniatti ML, Trotta F, Govoni M (2008) Single photon emission computed tomography and magnetic resonance imaging evaluation in SLE patients with and without neuropsychiatric involvement. Rheumatology (Oxford) 47:319–323CrossRef Castellino G, Padovan M, Bortoluzzi A, Borrelli M, Feggi L, Caniatti ML, Trotta F, Govoni M (2008) Single photon emission computed tomography and magnetic resonance imaging evaluation in SLE patients with and without neuropsychiatric involvement. Rheumatology (Oxford) 47:319–323CrossRef
6.
Zurück zum Zitat Joint National Committee on Prevention, Detection Evaluation and Treatment of High Blood Pressure (JNC-V1) (1997) Sixth report. Arch Intern Med. 157:2413–2446 Joint National Committee on Prevention, Detection Evaluation and Treatment of High Blood Pressure (JNC-V1) (1997) Sixth report. Arch Intern Med. 157:2413–2446
7.
Zurück zum Zitat World Health Organization (1997) Obesity: preventing and managing the global epidemic. World health Organization Geneva World Health Organization (1997) Obesity: preventing and managing the global epidemic. World health Organization Geneva
8.
Zurück zum Zitat The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–1197 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–1197
9.
Zurück zum Zitat Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) (2001) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) (2001) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497
10.
Zurück zum Zitat Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al (1999) International consensus statement on preliminary classification criteria for definitive antiphospholipid syndrome. Arthritis Rheum 42:1309–1311PubMedCrossRef Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al (1999) International consensus statement on preliminary classification criteria for definitive antiphospholipid syndrome. Arthritis Rheum 42:1309–1311PubMedCrossRef
11.
Zurück zum Zitat Horbach DA, Oort E, Donders RC, Derksen RH, de Groot PG (1996) Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus (comparison between different assays for the detection of antiphospholipid antibodies). Thromb Haemost 76:916–924PubMed Horbach DA, Oort E, Donders RC, Derksen RH, de Groot PG (1996) Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus (comparison between different assays for the detection of antiphospholipid antibodies). Thromb Haemost 76:916–924PubMed
12.
Zurück zum Zitat Karassa FB, Ioannidis JPA, Touloumi G, Boki KA, Moutsopoulos HM (2000) Risk factors for central nervous system involvement in systemic lupus erythematosus. Q J Med 93:169–174CrossRef Karassa FB, Ioannidis JPA, Touloumi G, Boki KA, Moutsopoulos HM (2000) Risk factors for central nervous system involvement in systemic lupus erythematosus. Q J Med 93:169–174CrossRef
13.
Zurück zum Zitat Vlachoyiannopoulos PG, Karassa FB, Karakostas KX, Drosos AA, Moutsopoulos HM (1993) Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients. Lupus 2:303–312PubMedCrossRef Vlachoyiannopoulos PG, Karassa FB, Karakostas KX, Drosos AA, Moutsopoulos HM (1993) Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients. Lupus 2:303–312PubMedCrossRef
14.
Zurück zum Zitat West SG, Emlen W, Wener MH, Kotzin BL (1995) Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 99:155–163CrossRef West SG, Emlen W, Wener MH, Kotzin BL (1995) Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 99:155–163CrossRef
15.
Zurück zum Zitat Toubi E, Khamashta MA, Panarra A, Hughes GR (1995) Association of antiphospholipid antibody with central nervous system disease in systemic lupus erythematosus. Am J Med 99:243–248CrossRef Toubi E, Khamashta MA, Panarra A, Hughes GR (1995) Association of antiphospholipid antibody with central nervous system disease in systemic lupus erythematosus. Am J Med 99:243–248CrossRef
16.
Zurück zum Zitat Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, Hughes GR (2003) Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 30:985–992PubMed Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, Hughes GR (2003) Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 30:985–992PubMed
17.
Zurück zum Zitat Brey RL, Holliday SL, Saklad AR et al (2002) Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 58:1214–1220PubMed Brey RL, Holliday SL, Saklad AR et al (2002) Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 58:1214–1220PubMed
19.
Zurück zum Zitat Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, Hughes GR (2003) Central nervous system involvement in the antiphospholipid antibodies syndrome. Rheumatology 42:200–213PubMedCrossRef Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, Hughes GR (2003) Central nervous system involvement in the antiphospholipid antibodies syndrome. Rheumatology 42:200–213PubMedCrossRef
20.
Zurück zum Zitat Trotta F, Dovigo L, Govoni M et al (1997) Neuropsychiatric involvement in systemic lupus erythematosus. A clinical and instrumental study in 116 North Italian Patients. Eur J Intern Med 8:95–103 Trotta F, Dovigo L, Govoni M et al (1997) Neuropsychiatric involvement in systemic lupus erythematosus. A clinical and instrumental study in 116 North Italian Patients. Eur J Intern Med 8:95–103
21.
Zurück zum Zitat Karassa F, Ioannidis J, Boki K et al (2000) Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med 109:628–634PubMedCrossRef Karassa F, Ioannidis J, Boki K et al (2000) Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med 109:628–634PubMedCrossRef
22.
Zurück zum Zitat Mikdashi J, Handwerger B (2004) Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology 43:1555–1560PubMedCrossRef Mikdashi J, Handwerger B (2004) Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology 43:1555–1560PubMedCrossRef
23.
Zurück zum Zitat Sergent JS, Lockshin MD, Klempner MS, Lypsky BA (1975) Central nervous system disease in SLE: therapy and prognosis. Am J Med 58:644–654PubMedCrossRef Sergent JS, Lockshin MD, Klempner MS, Lypsky BA (1975) Central nervous system disease in SLE: therapy and prognosis. Am J Med 58:644–654PubMedCrossRef
24.
Zurück zum Zitat Sibley JT, Olszynsky WP, Decoteau WE, Sundaram MB (1992) The incidence and prognosis of central nervous system in SLE. J Rheumatol 19:47–52PubMed Sibley JT, Olszynsky WP, Decoteau WE, Sundaram MB (1992) The incidence and prognosis of central nervous system in SLE. J Rheumatol 19:47–52PubMed
25.
Zurück zum Zitat Brunner HI, Silverman ED, To T et al (2002) Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 46:436–444CrossRef Brunner HI, Silverman ED, To T et al (2002) Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 46:436–444CrossRef
26.
Zurück zum Zitat Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB (1976) Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine 55:323–339PubMedCrossRef Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB (1976) Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine 55:323–339PubMedCrossRef
27.
Zurück zum Zitat Yee CS, Hussein H, Skan J, Skan J, Bowman S, Situayake D, Gordon C (2003) Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology 42:276–279PubMedCrossRef Yee CS, Hussein H, Skan J, Skan J, Bowman S, Situayake D, Gordon C (2003) Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology 42:276–279PubMedCrossRef
28.
Zurück zum Zitat Schiffer LE, Hussain N, Wang X, Huang W, Sinha J, Ramanujam M, Davidson A (2002) Lowering anti-dsDNA antibodies-what’s new? Lupus 11:885–894PubMedCrossRef Schiffer LE, Hussain N, Wang X, Huang W, Sinha J, Ramanujam M, Davidson A (2002) Lowering anti-dsDNA antibodies-what’s new? Lupus 11:885–894PubMedCrossRef
29.
Zurück zum Zitat Tektonidou MG, Ioannidis JPA, Boki KA, Vlachoyiannopoulos PG, Moutsopoulos HM (2000) Prognostic factors and clustering of serious clinical outcomes in antiphospholipid antibodies syndrome. Q J Med 93:523–530CrossRef Tektonidou MG, Ioannidis JPA, Boki KA, Vlachoyiannopoulos PG, Moutsopoulos HM (2000) Prognostic factors and clustering of serious clinical outcomes in antiphospholipid antibodies syndrome. Q J Med 93:523–530CrossRef
30.
Zurück zum Zitat McLaurin EY, Holliday SL, Williams P, Brey RL (2005) Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 64:297–303PubMedCrossRef McLaurin EY, Holliday SL, Williams P, Brey RL (2005) Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 64:297–303PubMedCrossRef
31.
Zurück zum Zitat Tomietto P, Annese V, D’Agostini S, Venturini P, La Torre G, De Vita S, Ferraccioli GF (2007) General and specific factor associated with severity of cognitive impairment in systemic lupus erythematosus. Arthritis Rheum 57:1461–1472PubMedCrossRef Tomietto P, Annese V, D’Agostini S, Venturini P, La Torre G, De Vita S, Ferraccioli GF (2007) General and specific factor associated with severity of cognitive impairment in systemic lupus erythematosus. Arthritis Rheum 57:1461–1472PubMedCrossRef
32.
Zurück zum Zitat Mikdashi J, Krumholz A, Handwerger B (2005) Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology 64:2102–2107PubMedCrossRef Mikdashi J, Krumholz A, Handwerger B (2005) Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology 64:2102–2107PubMedCrossRef
33.
Zurück zum Zitat McNicholl M, Glynn D, Mongey AB, Hutchinson M, Bresnihan B (1994) A prospective study of neurophysiologic, neurologic and immunologic abnormalities in systemic lupus erythematosus. J Rheumatol 21:1061–1066PubMed McNicholl M, Glynn D, Mongey AB, Hutchinson M, Bresnihan B (1994) A prospective study of neurophysiologic, neurologic and immunologic abnormalities in systemic lupus erythematosus. J Rheumatol 21:1061–1066PubMed
34.
Zurück zum Zitat Ferraccioli G, Di Poi E, Di Gregorio F, Giacomuzzi F, Guerra U (1999) Changes in regional cerebral blood flow after a cold hand test in systemic lupus erythematosus patients with Raynaud’s syndrome. Lancet 354:2135–2136PubMedCrossRef Ferraccioli G, Di Poi E, Di Gregorio F, Giacomuzzi F, Guerra U (1999) Changes in regional cerebral blood flow after a cold hand test in systemic lupus erythematosus patients with Raynaud’s syndrome. Lancet 354:2135–2136PubMedCrossRef
35.
Zurück zum Zitat Mathieu A, Sanna G, Passiu G, Cauli A, Piga M (2000) Raynaud’s syndrome in systemic lupus erythematosus. Lancet 355:1102–1103PubMedCrossRef Mathieu A, Sanna G, Passiu G, Cauli A, Piga M (2000) Raynaud’s syndrome in systemic lupus erythematosus. Lancet 355:1102–1103PubMedCrossRef
36.
Zurück zum Zitat Annese V, Tomietto P, Venturini P, D’Agostini S, Ferraccioli GF (2006) Migraine in SLE: role of antiphospholipid antibodies and Raynaud’s phenomenon. Reumatismo 58:50–58PubMed Annese V, Tomietto P, Venturini P, D’Agostini S, Ferraccioli GF (2006) Migraine in SLE: role of antiphospholipid antibodies and Raynaud’s phenomenon. Reumatismo 58:50–58PubMed
37.
Zurück zum Zitat Shoenfeld Y (2007) To smell autoimmunity: anti-P-ribosomal autoantibodies, depression, and the olfactory system. J Autoimmun 28:165–169PubMedCrossRef Shoenfeld Y (2007) To smell autoimmunity: anti-P-ribosomal autoantibodies, depression, and the olfactory system. J Autoimmun 28:165–169PubMedCrossRef
38.
Zurück zum Zitat Meroni PL, Shoenfeld Y (2008) Predictive, protective, orphan autoantibodies: the example of anti-phospholipid antibodies. Autoimmun Rev 7:585–587PubMedCrossRef Meroni PL, Shoenfeld Y (2008) Predictive, protective, orphan autoantibodies: the example of anti-phospholipid antibodies. Autoimmun Rev 7:585–587PubMedCrossRef
39.
Zurück zum Zitat Briani C, Lucchetta M, Ghirardello A, Toffanina E, Zampieri S, Ruggero S, Scarlato M, Quattrini A, Bassi N, Ermani M, Battistini L, Doria A (2009) Neurolupus is associated with anti-ribosomal P protein antibodies: an inception color study. J Autoimmun 32:79–84PubMedCrossRef Briani C, Lucchetta M, Ghirardello A, Toffanina E, Zampieri S, Ruggero S, Scarlato M, Quattrini A, Bassi N, Ermani M, Battistini L, Doria A (2009) Neurolupus is associated with anti-ribosomal P protein antibodies: an inception color study. J Autoimmun 32:79–84PubMedCrossRef
40.
Zurück zum Zitat Katzav A, Ben-Ziv T, Chapman J, Blank M, Reichlin M, Shoenfeld Y (2008) Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS-SLE (depression). J Autoimmun 31:393–398PubMedCrossRef Katzav A, Ben-Ziv T, Chapman J, Blank M, Reichlin M, Shoenfeld Y (2008) Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS-SLE (depression). J Autoimmun 31:393–398PubMedCrossRef
Metadaten
Titel
Factors and comorbidities associated with central nervous system involvement in systemic lupus erythematosus: a retrospective cross-sectional case–control study from a single center
verfasst von
Melissa Padovan
Gabriella Castellino
Alessandra Bortoluzzi
Luisa Caniatti
Francesco Trotta
Marcello Govoni
Publikationsdatum
01.01.2012
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 1/2012
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1565-4

Weitere Artikel der Ausgabe 1/2012

Rheumatology International 1/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.